Unleashing the science of payloads
for next-gen ADCs
Elikya Therapeutics is focused on the development of first-in-class toxic payloads for Antibody Drug Conjugates and intra-tumoral therapies with novel and differentiated mechanisms of action against cancer cells and tumoral micro-environment.
Elikya Therapeutics, A Landmark BioVentures Company
Our vision
Tackling the Innovation Gap in ADCs
Despite strong momentum around ADCs, the payload field lacks innovation to continue delivering effective treatments.
Elikya Therapeutics addresses this challenge by creating ADCs leveraging its unique and patented first-in-class payload technology, setting a new standard in oncology therapy innovation.
Elikya Therapeutics is part of the Nexus of Landmark BioVentures.
